AcelRx Pharmaceuticals, Inc.:
U.S. launch of DSUVIA (sufentanil sublingual tablet 30 mcg) exp. 1Q19. Recently approved for mgmt of acute pain severe enough to require opioid analgesic (adult patients in certified medically supervised healthcare settings). Also developing Zalviso (Ph 3) in the US as an innovative patient-controlled analgesia system for moderate-to-severe acute pain in medically supervised settings.
Phase III, Registration Stage
Biotechnology, Medical Device, Specialty Pharmaceutical
100MM - 500MM
351 Galveston Drive
Redwood City, CA 94063
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by